RecruitingPhase 1Phase 2NCT07435038

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.

Sponsor

Betta Pharmaceuticals Co., Ltd.

Enrollment

120 participants

Start Date

Jan 29, 2026

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors Colorectal Cancer (CRC)

Summary

Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BPI-572270 for people with advanced solid tumors, colorectal cancer (crc), and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.